117 related articles for article (PubMed ID: 38890129)
1. Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years.
Eberli FR; Oldroyd KG; Urban P; Krucoff MW; Morice MC; Tanguay JF; Leon MB; Brunel P; Maillard L; Lipiecki J; Cook S; Berland J; Hovasse T; Carrié D; Schütte D; Sadozai Slama S; Garot P
Open Heart; 2024 Jun; 11(1):. PubMed ID: 38890129
[TBL] [Abstract][Full Text] [Related]
2. Polymer-free Biolimus-A9 coated thin strut stents for patients at high bleeding risk 1-year results from the LEADERS FREE III study.
Eberli FR; Stoll HP; Urban P; Morice MC; Brunel P; Maillard L; Lipiecki J; Cook S; Berland J; Hovasse T; Carrie D; Schütte D; Slama SS; Garot P
Catheter Cardiovasc Interv; 2022 Feb; 99(3):593-600. PubMed ID: 34241947
[TBL] [Abstract][Full Text] [Related]
3. Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes.
Menown IBA; Mamas MA; Cotton JM; Hildick-Smith D; Eberli FR; Leibundgut G; Tresukosol D; Macaya C; Copt S; Slama SS; Oldroyd KG
J Interv Cardiol; 2021; 2021():6654515. PubMed ID: 33880087
[TBL] [Abstract][Full Text] [Related]
4. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study.
Garot P; Brunel P; Dibie A; Morelle JF; Abdellaoui M; Levy R; Carrié D; Karsenty B; Robin C; Berland J; Copt S; Sadozai Slama S; Oldroyd K; Morice MC; Lipiecki J;
Catheter Cardiovasc Interv; 2023 Jan; 101(1):60-71. PubMed ID: 36378683
[TBL] [Abstract][Full Text] [Related]
6. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
[TBL] [Abstract][Full Text] [Related]
7. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy.
Carrié D; Menown I; Oldroyd K; Copt S; Talwar S; Maillard L; Morice MC; Teik LS; Lang I; Urban P
JACC Cardiovasc Interv; 2017 Aug; 10(16):1633-1642. PubMed ID: 28838473
[TBL] [Abstract][Full Text] [Related]
10. Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study.
Krucoff MW; Urban P; Tanguay JF; McAndrew T; Zhang Y; Rao SV; Morice MC; Price MJ; Cohen DJ; Abdel-Wahab M; Mehta SR; Faurie B; McLaurin B; Diaz C; Stoll HP; Pocock S; Leon MB
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008603. PubMed ID: 32279567
[TBL] [Abstract][Full Text] [Related]
11. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
Grundeken MJ; Wykrzykowska JJ; Ishibashi Y; Garg S; de Vries T; Garcia-Garcia HM; Onuma Y; de Winter RJ; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Meier B; Jüni P; Yazdani A; Copt S; Windecker S; Serruys PW
Catheter Cardiovasc Interv; 2016 Jun; 87(7):E248-60. PubMed ID: 26649651
[TBL] [Abstract][Full Text] [Related]
12. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
Kornowski R; Konigstein M; Jonas M; Assali A; Vaknin-Assa H; Segev A; Danenberg H; Halabi M; Roguin A; Kerner A; Lev E; Karamasis GV; Johnson TW; Anderson R; Blaxill J; Jadhav S; Hoole S; Witberg G; Issever MO; Ben-Yehuda O; Baumbach A
J Am Heart Assoc; 2024 Jan; 13(2):e029051. PubMed ID: 38214256
[TBL] [Abstract][Full Text] [Related]
14. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
[TBL] [Abstract][Full Text] [Related]
15. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
[TBL] [Abstract][Full Text] [Related]
16. One-year performance of thin-strut cobalt chromium sirolimus-eluting stent versus thicker strut stainless steel biolimus-eluting coronary stent: a propensity-matched analysis of two international all-comers registries.
Vlieger S; Danzi GB; Kauer F; Oemrawsingh RM; Stojkovic S; IJsselmuiden AJJ; Routledge H; Laanmets P; Roffi M; Fröbert O; Baello P; Wlodarczak A; Puentes A; Polad J; Hildick-Smith D
Coron Artery Dis; 2021 Aug; 32(5):391-396. PubMed ID: 33060529
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
18. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
[TBL] [Abstract][Full Text] [Related]
19. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
[TBL] [Abstract][Full Text] [Related]
20. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
